Inclusion Criteria:  An informed consent document voluntarily signed and dated by the subject. Subject must understand and be able to read and write in English. Enrollment in residential treatment at study site. Subject must be voluntarily engaged in MAT through services rendered by the treatment facility (Gaudenzia, Inc.), including buprenorphine, naltrexone, or methadone. Physically healthy males and females, aged 18 or older, who meet criteria for opioid use disorder (based on Diagnostic and Statistical Manual 5th Edition criteria) as their primary diagnosis, who are enrolled in residential treatment at the collaborating study site. Subject must be willing to be randomized to treatment condition. Subjects who are willing and able to comply with scheduled visits and other study procedures.  Exclusion Criteria:  Meets current or lifetime DSM-V criteria for schizophrenia or any psychotic disorder or organic mental disorder, including dementia-related psychosis as determined by the semi-structured interview. Presence of any other psychiatric disorder that in the opinion of the PI will interfere with completion of the study or place the patient at heightened risk through participation in the study.